DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
TL;DR 摘要总结
研究通过检测脱落宫颈细胞中CDO1和CELF4基因的甲基化水平，评估其在绝经前异常子宫出血女性子宫内膜癌筛查中的价值。结果显示，双基因甲基化检测的敏感性和特异性分别为85.7%和87.6%，优于年龄、BMI和子宫内膜厚度等指标，联合应用可进一步提高筛查效率。
摘要 · Abstract
OBJECTIVE: The aim of our study was to explore the value of DNA (CDO1m/CELF4m) methylation detection in exfoliated cervical cells collected for screening endometrial cancer in premenopausal women with abnormal uterine bleeding
METHODS: A total of 296 premenopausal women with abnormal uterine bleeding admitted to the Department of Obstetrics and Gynecology at the Third Xiangya Hospital of Central South University from November 2021 to October 2022 were selected. Clinical characteristics, endometrial thickness measured by transvaginal ultrasound and serum CA125 were collected. Exfoliated cervical cells from the thinPrep cytogic test were collected for DNA (CDO1m/CELF4m) methylation testing. Endometrial tissue was collected under hysteroscopy for pathological diagnosis as the gold standard. A univariate logistic regression model was used to analyze risk factors for endometrial cancer. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to measure the diagnostic efficacy of DNA methylation detection in endometrial cancer screening of women with abnormal uterine bleeding
RESULTS: Univariate logistic regression analysis showed that age, body mass index (BMI) ��25?kg/m2, endometrial thickness ��11?mm, CDO1 methylation (CDO1m��Ct��8.4), CELF4 methylation (CELF4m��Ct��8.8), and dual gene methylation (CDO1m��Ct��8.4?or CELF4m��Ct��8.8) were independent risk factors for endometrial cancer in women with abnormal uterine bleeding. The odds ratio (OR) values (95%?confidence interval (CI) were 0.87 (0.80-0.95), 4.76 (1.89-11.96), 8.41 (3.13-22.59), 64.49 (20.46-203.33), 12.79 (4.91-33.30), and 42.53 (11.90-152.04), respectively. Among these indicators, dual gene methylation had the higher sensitivity and specificity for endometrial cancer screening (85.7% and 87.6%). Moreover, dual gene methylation combined with BMI or endometrial thickness could further improve the screening efficiency of endometrial cancer in women with abnormal uterine bleeding
CONCLUSIONS: In premenopausal women with abnormal uterine bleeding, the clinical efficacy of DNA (CDO1m/CELF4m) methylation detection in exfoliated cervical cells for endometrial cancer screening was better than that of other noninvasive clinical indicators. In addition, dual gene methylation combined with BMI or endometrial thickness was a good predictor of endometrial cancer screening.
发表单位
the Third Xiangya Hospital, Central South University
引用格式
Zhao, X., Yang, Y., Fu, Y., Lv, W. & Xu, D. DNA methylation detection is a significant biomarker for screening endometrial cancer in premenopausal women with abnormal uterine bleeding. Int J Gynecol Cancer 34, 1165–1171 (2024).
文献海报 · Poster
在新窗口查看
* 海报为中英双语，标题双语对照显示；可在海报右上角切换 EN / 中文，语言自动适配当前页面。